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119beneﬁcial compensatory response to altered systemic
metabolic changes in obesity needs further evalua-
tion. Our results also conﬁrm those obtained for
skeletal muscle, with reversal of systemic and muscle
metabolic derangements only 9 months after BS (3).
The improvement in life-style habits may have
also contributed to the late reduction in cardiac
steatosis. Compared with usual care, BS is the most
effective treatment for severe obesity, and the long-
term results regarding reduction of cardiovascular
mortality have been well established. To the best of
our knowledge, this study is the ﬁrst to show a
signiﬁcant improvement in all types of ectopic fat
depots, even cardiac steatosis, long-term after BS.
Whether these improvements participate in the
reduction of cardiovascular risk and mortality in
obese patients needs to be conﬁrmed.Ines Abdesselam
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Guidelines Stated MattersWe read with interest the recently published report of
the multicenter randomized controlled trial (RCT)
known as PRECISE-IVUS (plaque regression with
cholesterol absorption inhibitor or synthesis inhibitorevaluated by intravascular ultrasound) (1). While we
noted that coronary angiographic outcomes in those
assigned to combination statin plus ezetemibe ther-
apy compared favorably to those assigned statin
monotherapy, we were concerned that the authors
did not refer to the 2013 ACC/AHA guidelines in an
accurate fashion. Our evidence-based guidelines were
not “ﬁre and forget” as the authors write in their
discussion. Moreover, they express a serious
misconception about what the guidelines actually
said about nonstatins.
In both the guideline recommendations tables, key
ﬁgures (Figure 3 entitled Initiating Statin Therapy in
Individuals with Clinical ASCVD, and Figure 5 entitled
Statin Therapy: Monitoring Therapeutic Response
and Adherence), and in the text, we indicate clearly
what the recommendations and workﬂow are for
secondary prevention patients (2).
We think it is crucial that readers understand what
the guidelines recommended. Figure 3 shows that in
secondary prevention patients, the clinician initiates
high-intensity statin therapy if age #75 years and
without contraindications, conditions, or drug-drug
interactions inﬂuencing statin safety or a history of
statin intolerance. In addition to statin therapy, life-
style counseling was also recommended. In Figure 5
whose title alone indicates that the phrase “Fire and
Forget It” does not refer to the 2013 ACC-AHA
guidelines, it clearly shows that the guidelines
recommend a follow-up lipid panel 4 to 12 weeks after
initiation of statin therapy to assess both response to
therapy (the anticipated response to high-intensity
statin therapy was given as a $50% reduction in
low-density lipoprotein cholesterol [LDL-C]) and as a
baseline for adherence.
If the ACC/AHA cholesterol guidelines were fol-
lowed in the participants in this trial, the antici-
pated LDL-C would have been approximately in the
mid-50 mg/dl range since baseline LDL-C in both
the LZ and L group were 109.8 and 108.3 mg/dl,
respectively. Mindful that not everyone tolerates
high-intensity statins, the guidelines addressed the
situation where statin intolerance would occur. It
speciﬁcally noted: “Clinicians treating high-risk
patients who have a less-than-anticipated response
to statins, who are unable to tolerate a less-than-
recommended intensity of a statin, or who are com-
pletely statin intolerant, may consider the addition
of a nonstatin cholesterol-lowering therapy. High-risk
individuals include those with ASCVD, those with
LDL-C $190 mg/dl, and those with diabetes 40 to
75 years of age. In this situation, this guideline rec-
ommends clinicians preferentially prescribe drugs
that have been shown in RCTs to provide ASCVD
Letters J A C C V O L . 6 7 , N O . 1 , 2 0 1 6
J A N U A R Y 5 / 1 2 , 2 0 1 6 : 1 1 6 – 2 5
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for adverse effects and drug-drug interactions, and
consider patient preference.” Based on the ﬁndings of
IMPROVE-IT (Improved Reduction of Outcomes:
Vytorin Efﬁcacy International Trial) (3), ezetemibe
would qualify as a nonstatin to be considered with a
lower intensity, but tolerated statin in high-risk groups
such as those with coronary atherosclerotic disease.
Thus, the data from this intravascular ultrasound trial
are consistent with what the guidelines recommend if
a high-intensity statin cannot be tolerated.
Lastly, there is an implied misconception of the
panel’s recommendation regarding lipid targets. The
ACC/AHA guidelines stated that “the Expert Panel
makes no recommendations for or against speciﬁc
LDL-C or non–HDL-C targets for the primary or sec-
ondary prevention of ASCVD.” The guidelines go
beyond stating that lower LDL-C is better; rather they
recommend a strategy for achieving a lower LDL-C
that can be safely attained with therapies (lifestyle
and medication) proven to provide acceptable net
beneﬁt. For example, trials of niacin added to statin
therapy that achieved lower LDL-C levels by adding
Niacin as compared to placebo, did not show net
beneﬁt. Thus, the cholesterol guidelines endorse
“lower is better, but it matters how you get there and
whether the beneﬁt outweighs the risk for that
patient” (4).*Neil J. Stone, MD
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Stated MattersWe have read with great interest the letter by
Dr. Stone and colleagues commenting on our recent
paper (1), and we greatly appreciate their valuable
comments on the interpretation of 2013 American
College of Cardiology/American Heart Association
(ACC/AHA) cholesterol guideline (2). Especially per-
taining to the “Fire and Forget It” concept mislead-
ingly disseminated among the clinicians, it is of
clinical importance that the expert panel members
clearly recommend in this letter a follow-up lipid
panel 4 to 12 weeks after initiation of statin therapy
to assess both response to therapy (the anticipated
response to high-intensity statin therapy was given
as a $50% reduction in low-density lipoprotein
cholesterol [LDL-C]) and as a baseline for adherence.
In addition, Drs. Stone, Lloyd-Jones, and Smith
emphasized that the ACC/AHA guideline endorse
“lower is better, but it matters how you get there and
whether the beneﬁt outweighs the risk for that
patient.”
In terms of the speciﬁc LDL-C treatment goals in
secondary prevention, we totally agree with the
guideline statement: the expert panel was unable to
ﬁnd robust evidence to support continued use of
speciﬁc LDL-C treatment targets (<100 mg/dl or
<70 mg/dl). In a recent meta-analysis of statin trials
(3), however, among 38,153 participants treated with
high-dose statin therapy, patients who achieve very
low LDL-C levels have a lower risk for major cardio-
vascular events than do those achieving moderately
low levels, and >40% did not reach an LDL-C
target <70 mg/dl, reafﬁrming “the lower, the better”
and the limitation of statin monotherapy. Further-
more, based on the safety and signiﬁcant clinical net
beneﬁt of combination of statin/ezetimibe evidenced
by IMPROVE-IT (Improved Reduction of Outcomes
Vytorin Efﬁcacy International Trial) (4) and PRECISE-
IVUS (Plaque Regression With Cholesterol Absorption
Inhibitor or Synthesis Inhibitor Evaluated by Intra-
vascular Ultrasound) (1) trials in contrast with
HPS2-THRIVE (Heart Protection Study 2–Treatment of
HDL to Reduce the Incidence of Vascular Events) trial
(5), ezetimibe added to statin therapy would qualify
as a promising non-statin agent to be considered in
high-risk patients such as those with coronary
atherosclerotic disease.
Finally, we would like to thank Drs. Stone,
Lloyd-Jones, and Smith again for the letter which
promoted for us and the readers of our article
the accurate interpretation of the 2013 ACC/AHA
cholesterol guideline.
